Natural S-equol decreases bone resorption in postmenopausal, non-equol-producing Japanese women

Tousen, Yuko; Ezaki, Junko; Fujii, Yasuhiro; Ueno, Tomomi; Nishimuta, Mamoru; Ishimi, Yoshiko

doi:10.1097/gme.0b013e3181f85aa7

Cited by 123 publications

(98 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…98 In addition, it was also believed that the difference in ability to produce equol between equol producers and nonequol producers is mainly based on the interindividual differences of the intestinal bacteria. 92 A 2-year study also showed that equol-producing intestinal bacteria had no benefit in women who were equol producers. Only women whose 25-hydroxyvitamin D baseline levels were <20 ng/ mL had a smaller rate of spinal bone loss in those receiving SI treatment compared with the placebo group.…”

Section: Study Populationmentioning

confidence: 99%

“…91 Equol is not produced in all healthy humans as only 30-60% of the population can produce equol, and production is higher among Asians and vegetarians. 92 Equol and O-desmethylangolensin (ODMA) producers were defined as those people with detectable equol (87.5 ng/mL or 362 nM) and ODMA (87.5 ng/mL, or 399 nM) in their urine. 93 Equol possesses more estrogen-like proteins than DAN and plays a crucial role in the soy phytoestrogen efficacy.…”

Section: Study Populationmentioning

confidence: 99%

See 1 more Smart Citation

Soy Isoflavones and Osteoporotic Bone Loss: A Review with an Emphasis on Modulation of Bone Remodeling

Zheng

Lee

Chun

2016

Journal of Medicinal Food

130

View full text Add to dashboard Cite

Osteoporosis is an age-related disorder that affects both women and men, although estrogen deficiency induced by menopause accelerates bone loss in older women. As the demographic shifts to a more aged population, a growing number of men and women will be afflicted with osteoporosis. Since the current drug therapies available have multiple side effects, including increased risk of developing certain types of cancer or complications, a search for potential nonpharmacologic alternative therapies for osteoporosis is of prime interest. Soy isoflavones (SI) have demonstrated potential bone-specific effects in a number of studies. This article provides a systematic review of studies on osteoporotic bone loss in relation to SI intake from diet or supplements to comprehensively explain how SI affect the modulation of bone remodeling. Evidence from epidemiologic studies supports that dietary SI attenuate menopause-induced osteoporotic bone loss by decreasing bone resorption and stimulating bone formation. Other studies have also illustrated that bone site-specific trophic and synergistic effects combined with exercise intervention might contribute to improve the bioavailability of SI or strengthen the bonespecific effects. To date, however, the effects of dietary SI on osteoporotic bone loss remain inconclusive, and study results vary from study to study. The current review will discuss the potential factors that result in the conflicting outcomes of these studies, including dosages, intervention materials, study duration, race, and genetic differences. Further well-designed studies are needed to fully understand the underlying mechanism and evaluate the effects of SI on osteoporosis in humans.

show abstract

Section: Study Populationmentioning

confidence: 99%

Section: Study Populationmentioning

confidence: 99%

Soy Isoflavones and Osteoporotic Bone Loss: A Review with an Emphasis on Modulation of Bone Remodeling

Zheng

Lee

Chun

2016

Journal of Medicinal Food

130

View full text Add to dashboard Cite

show abstract

“…Isoflavones are one of the phytoestrogens that are possible preventive factors in several hormone-dependent cancers such as prostate cancer and breast cancer (Zhu et al, 2011;Khan et al, 2012 ), cardiovascular disease (Wong et al, 2012;Usui et al, 2013), menopausal symptoms (Aso et al, 2012;Jenks et al, 2012), and osteoporosis (Scheiber et al, 2001;Tousen et al, 2011). Especially, genistein and daidzein, which are aglycones of isoflavones, were found to have potential roles in the prevention of prostate cancer (Akaza et al, 2004;Nagata et al, 2007;Gardner et al, 2009).…”

Section: Introductionmentioning

confidence: 99%

Counts of Slackia sp. strain NATTS in Intestinal Flora are Correlated to Serum Concentrations of Equol both in Prostate Cancer Cases and Controls in Japanese Men

Sugiyama¹,

Nagata²,

Fukuta³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Isoflavones, which are included in soybeans, have been suggested to protect against prostate cancer. Equol, one of isoflavones, is an intestinally derived bacterial metabolite of daidzein. A newly identified equol-producing bacterium, Slackia sp. strain NATTS, with a high equol-producing activity was isolated from human feces in Japanese adults. Counts of Slackia sp. strain NATTS in intestinal flora have not been assessed with regard to prostate cancer risk. In this study, we investigated the association of serum isoflavones and counts of Slackia sp. strain NATTS with prostate cancer risk in a case-control study. Materials and Methods: Concentrations of isoflavones and counts of Slackia sp. strain NATTS in feces were measured from 44 patients with prostate cancer and 28 hospital controls. The risk of prostate cancer was evaluated in terms of odds ratios (ORs) and 95% confidence intervals (CIs) by the logistic regression analysis. Results: The detection proportions of Slackia sp. strain NATTS in cases and controls were 34.1% and 25.0%, respectively. Counts of Slackia sp. strain NATTS were significantly correlated with serum concentrations of equol both in cases and controls (Spearman correlation coefficients, r s =0.639 and r s =0.572, p<0.01, respectively). Serum concentrations of genistein, daidzein, glycitein, and equol were not significantly associated with risk of prostate cancer. Conclusions: This study found that counts of Slackia sp. strain NATTS correlated with serum concentrations of equol both in prostate cancer cases and controls, but serum isoflavone concentrations were not associated with risk of prostate cancer in our patients.

show abstract

“…Among these, five were published in Chinese and no translation into an EU language was available (Dong et al, 2008;Gao et al, 2006;Xin and Yang, 2006;Ye et al, 2006;Yi and Shu, 2004), one was of three months duration (Uesugi et al, 2003), one was conducted in pre-menopausal women (Anderson et al, 2002), one primarily (85 % of subjects) in males (Newton et al, 2006), one used an isoflavone metabolite (S-equol) as intervention (Tousen et al, 2011), and one was a single-arm, open label, uncontrolled study (Scheiber et al, 2001). The Panel considers that no conclusions can be drawn from these studies for the scientific substantiation of the claim.…”

Section: Maintenance Of Bone Mineral Density (Id 1655)mentioning

confidence: 99%

Scientific Opinion on the substantiation of health claims related to soy isoflavones and maintenance of bone mineral density (ID 1655) and reduction of vasomotor symptoms associated with menopause (ID 1654, 1704, 2140, 3093, 3154, 3590) (further assessmen

Products¹

2012

EFSA Journal

View full text Add to dashboard Cite

Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to provide a scientific opinion on health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 in the framework of further assessment related to soy isoflavones and maintenance of bone mineral density and reduction of vasomotor symptoms associated with menopause. The food constituent that is the subject of the claim, soy isoflavones, is sufficiently characterised. The claimed effects, maintenance of bone mineral density and reduction of vasomotor symptoms associated with menopause, which are eligible for further assessment, are beneficial physiological effects. The proposed target populations are peri‐ and/or post‐menopausal women. On the basis of the data presented, the Panel concludes that the evidence provided is insufficient to establish a cause and effect relationship between the consumption of soy isoflavones and maintenance of bone mineral density, and between the consumption of soy isoflavones and reduction of vasomotor symptoms associated with menopause.

show abstract

Natural S-equol decreases bone resorption in postmenopausal, non-equol-producing Japanese women

Abstract: These findings suggest that 10 mg/day of natural S-equol supplementation contributes to bone health in non-equol-producing postmenopausal women without adverse effects.

Cited by 123 publications

References 43 publications

Soy Isoflavones and Osteoporotic Bone Loss: A Review with an Emphasis on Modulation of Bone Remodeling

Soy Isoflavones and Osteoporotic Bone Loss: A Review with an Emphasis on Modulation of Bone Remodeling

Counts of Slackia sp. strain NATTS in Intestinal Flora are Correlated to Serum Concentrations of Equol both in Prostate Cancer Cases and Controls in Japanese Men

Scientific Opinion on the substantiation of health claims related to soy isoflavones and maintenance of bone mineral density (ID 1655) and reduction of vasomotor symptoms associated with menopause (ID 1654, 1704, 2140, 3093, 3154, 3590) (further assessmen

Contact Info

Product

Resources

About